A patient with newly diagnosed invasive ductal carcinoma and a confirmed BRCA2 mutation is experiencing fatigue and shortness of breath. Diagnostic imaging suggests possible metastatic spread. Considering her anemia and poorly controlled hypertension, which intervention should the nurse prioritize to optimize her current health status?

D) Arrange for a consultation with a cardiologist to address her hypertension and anemia.

A) Initiate an iron-rich diet to improve her hemoglobin levels.

B) Educate the patient about the importance of adhering to antihypertensive medications.

C) Collaborate with the oncology team to discuss the initiation of systemic chemotherapy.

D) Arrange for a consultation with a cardiologist to address her hypertension and anemia.

A 55-year-old female with a recent diagnosis of invasive ductal carcinoma and a confirmed BRCA2 mutation is experiencing fatigue and has a hemoglobin level of 10.5 g/dL. Her blood pressure is 155/100 mmHg despite adherence to antihypertensive medication. Considering her current condition and diagnostic results, what is the most appropriate nursing intervention to address her symptoms and treatment needs?

C) Coordinate with the oncology team to initiate chemotherapy to address the metastatic disease.

A) Increase the dosage of her antihypertensive medication to better control her blood pressure.

B) Recommend iron supplementation to address her anemia and improve fatigue.

C) Coordinate with the oncology team to initiate chemotherapy to address the metastatic disease.

D) Arrange for genetic counseling to discuss the implications of her BRCA2 mutation with her family.

A patient undergoing chemotherapy presents with increased fatigue, dizziness, and palpitations. Her hemoglobin level is 9.8 g/dL, and she has a blood pressure of 160/105 mmHg with a heart rate of 110 beats per minute. An echocardiogram reveals a mildly reduced ejection fraction of 50%. Which nursing intervention is most appropriate to prioritize for this patient?

C) Monitor cardiac rhythms closely and report any significant changes to the physician.

A) Administer a diuretic to manage fluid overload and reduce cardiac strain.

B) Initiate dietary counseling to increase iron intake and address anemia.

C) Monitor cardiac rhythms closely and report any significant changes to the physician.

D) Educate the patient on the importance of medication adherence for hypertension management.

A patient undergoing chemotherapy presents with increased fatigue, dizziness, palpitations, hypertension, and a drop in hemoglobin. An echocardiogram shows a mildly reduced ejection fraction of 50%. Which nursing intervention is the priority to address her current symptoms?

B) Monitor the patient's cardiac status and vital signs closely.

A) Administer iron supplementation to address anemia.

B) Monitor the patient's cardiac status and vital signs closely.

C) Educate the patient on dietary modifications to improve hemoglobin levels.

D) Initiate an erythropoietin-stimulating agent to increase red blood cell production.

A patient undergoing chemotherapy presents with persistent tachycardia, elevated blood pressure, and anemia. The healthcare team decides to initiate a low-dose beta-blocker and a potassium-sparing diuretic. Which nursing assessment finding is most crucial to report to the healthcare provider to prevent potential complications?

A) Increased fatigue and shortness of breath

B) Blood pressure reading of 140/90 mmHg

C) Heart rate of 90 beats per minute

D) Serum potassium level of 5.0 mEq/L

A patient undergoing chemotherapy for cancer treatment presents with persistent tachycardia, elevated blood pressure, and anemia despite iron supplementation. The healthcare team plans to initiate a low-dose beta-blocker and a potassium-sparing diuretic. As the nurse caring for this patient, which action is the most appropriate to prioritize in their care plan?

C) Assess the patient's orthostatic blood pressure regularly to evaluate the effectiveness of the antihypertensive therapy.

A) Monitor the patient's blood glucose levels closely due to potential beta-blocker effects.

B) Teach the patient to avoid potassium-rich foods to prevent hyperkalemia from the potassium-sparing diuretic.

C) Assess the patient's orthostatic blood pressure regularly to evaluate the effectiveness of the antihypertensive therapy.

D) Encourage increased fluid intake to manage the anemia and improve circulatory volume.

A patient undergoing chemotherapy presents with fatigue, mild ankle swelling, and occasional shortness of breath when climbing stairs. Her echocardiogram shows a mild reduction in left ventricular ejection fraction at 50%. Which nursing intervention is most appropriate to address her current symptoms and support her cardiac function?

B) Educate the patient on energy conservation techniques to manage fatigue

A) Encourage a high-sodium diet to manage blood pressure

B) Educate the patient on energy conservation techniques to manage fatigue

C) Advise the patient to increase fluid intake to manage swelling

D) Recommend daily vigorous exercise to improve cardiovascular endurance

A patient undergoing chemotherapy presents with mild swelling in the ankles and occasional shortness of breath when climbing stairs. Her blood pressure is 145/90 mmHg, and a recent echocardiogram reveals a mild reduction in left ventricular ejection fraction at 50%. Which nursing intervention is most appropriate to address the patient's symptoms and prevent further cardiac complications?

D) Instruct the patient to monitor weight daily and report any sudden increases.

A) Encourage increased fluid intake to promote renal function.

B) Educate the patient on the importance of low-sodium diet to reduce fluid retention.

C) Suggest the patient engage in daily strenuous exercise to improve cardiovascular health.

D) Instruct the patient to monitor weight daily and report any sudden increases.

A patient undergoing chemotherapy presents with increased shortness of breath, dry cough, and mild pitting edema. The healthcare team has adjusted her medications to include a potassium-sparing diuretic and a low-dose ACE inhibitor. What should the nurse prioritize in the patient's care plan to monitor for potential complications associated with these medications?

A) Monitor the patient's potassium levels and watch for signs of hyperkalemia.

B) Assess the patient for signs of gastrointestinal bleeding.

C) Encourage increased fluid intake to prevent dehydration.

D) Monitor the patient for signs of hypoglycemia.

A patient undergoing chemotherapy presents with increased shortness of breath, a persistent dry cough, and mild pitting edema. The patient's chest X-ray shows mild pulmonary congestion and a slight increase in heart size. BNP levels are mildly elevated. The healthcare team adjusts the patient's treatment by increasing the dosage of a potassium-sparing diuretic and adding a low-dose ACE inhibitor. What is the primary nursing consideration when monitoring this patient for potential complications associated with these medication changes?

A) Monitor for signs of hyperkalemia, such as muscle weakness and cardiac arrhythmias.

B) Assess for signs of hypotension, particularly postural hypotension.

C) Evaluate for signs of fluid overload, such as worsening edema and crackles in the lungs.

D) Check for signs of acute kidney injury, including elevated creatinine levels.

breast cancer - Nursing Case Study

Pathophysiology

• Primary mechanism: Genetic mutations in breast cells, such as BRCA1 and BRCA2 mutations, lead to abnormal cell growth and division, forming a tumor. These mutations disrupt DNA repair processes, increasing cancer risk.

• Secondary mechanism: Hormonal influence, particularly estrogen, can promote the growth of hormone receptor-positive breast cancer. Estrogen binds to receptors on cancer cells, driving proliferation and survival.

• Key complication: Metastasis occurs when cancer cells invade nearby tissues or spread to distant organs via lymphatic or blood vessels, complicating treatment and reducing prognosis.

Patient Profile

Demographics:

45-year-old female, school teacher

History:

• Key past medical history: Hypertension, family history of breast cancer (mother)

• Current medications: Lisinopril, Metformin, Letrozole (aromatase inhibitor)

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Persistent breast pain and swelling

• Key symptoms: Fatigue, noticeable lump in the right breast, occasional shortness of breath

• Vital signs: Blood pressure 150/95 mmHg, heart rate 105 bpm, respiratory rate 22 breaths/min, temperature 99.1°F

Section 1

New Diagnostic Results:

Following the patient's presentation of persistent breast pain, swelling, and the discovery of a noticeable lump, further diagnostic imaging was performed. A mammogram and subsequent ultrasound of the right breast revealed a suspicious mass measuring 3.5 cm with irregular borders. A core needle biopsy was conducted, and histopathological analysis confirmed the presence of invasive ductal carcinoma, grade II, with estrogen receptor positivity. Genetic testing was also performed due to the patient's family history and confirmed a BRCA2 mutation, increasing her risk for both breast and ovarian cancers. This genetic finding has significant implications for treatment planning and family counseling.

Additionally, a PET scan was ordered to assess for potential metastasis given the patient's occasional shortness of breath and fatigue, symptoms that could indicate systemic involvement. The scan revealed increased metabolic activity in the right axillary lymph nodes and a small nodule in the right lung, suggesting likely metastatic spread. Laboratory tests revealed a hemoglobin level of 10.5 g/dL, indicating mild anemia, which could contribute to her fatigue. The patient's hypertension remains sub-optimally controlled, with a blood pressure reading of 155/100 mmHg, despite medication adherence.

These findings necessitate a multidisciplinary approach to management, incorporating oncology, genetics, and cardiology consultations. The focus will be on addressing the primary tumor while considering systemic therapy options to manage metastatic disease. The patient's treatment plan will need to balance aggressive cancer management with the management of her hypertension and potential anemia. This complex interplay of conditions and treatment requirements presents an opportunity for clinical reasoning to optimize her care pathway, emphasizing the importance of personalized medicine in her ongoing management.

Section 2

Change in Patient Status:

Three weeks into her treatment regimen, the patient presents with new symptoms that prompt further evaluation. She reports increased fatigue, dizziness, and a sense of palpitations. Her current vital signs reveal a blood pressure of 160/105 mmHg and a heart rate of 110 beats per minute, indicating worsening hypertension and possible tachycardia. Additionally, there is a noted pallor and a decrease in her energy levels, significantly impacting her daily activities. A follow-up complete blood count shows a further drop in hemoglobin to 9.8 g/dL, suggesting a progression of her anemia. Given her ongoing chemotherapy, these symptoms raise concerns about potential cardiotoxicity and bone marrow suppression, common side effects that require immediate attention.

The oncology team collaborates with cardiology to evaluate the possibility of chemotherapy-induced cardiac dysfunction. An echocardiogram is performed, revealing a mildly reduced ejection fraction of 50%, suggestive of early cardiotoxicity. This finding necessitates a reassessment of her chemotherapy regimen, considering the balance between effective cancer control and minimizing further cardiac compromise. Concurrently, her anemia is addressed with the initiation of iron supplementation and dietary modifications, alongside discussions about the potential need for erythropoietin-stimulating agents if her anemia persists or worsens.

These developments highlight the complexity of her treatment, necessitating continuous monitoring and adjustment of her therapeutic plan. The team prioritizes a holistic approach, integrating cardiology support and potential modifications to her antihypertensive regimen, to optimize her cardiovascular health while maintaining aggressive oncological management. The patient's evolving clinical picture underscores the need for vigilant assessment and timely interventions to prevent further complications, setting the stage for the next phase of her comprehensive care.

Section 3

Following the initial interventions, the patient returns for a follow-up two weeks later. She reports a slight improvement in energy levels, though she continues to experience episodes of dizziness and palpitations, particularly when standing quickly. Her blood pressure remains elevated at 155/100 mmHg despite adjustments to her antihypertensive regimen, and her heart rate has increased to 115 beats per minute, raising concerns about persistent tachycardia. A repeat complete blood count reveals a hemoglobin level of 9.5 g/dL, indicating that her anemia has not improved sufficiently with iron supplementation alone.

Further evaluation is conducted, including a 24-hour Holter monitor to assess her cardiac rhythm. The results show frequent premature ventricular contractions and occasional short runs of supraventricular tachycardia, which suggest an ongoing risk of arrhythmias potentially exacerbated by the chemotherapy. Her creatinine and electrolyte levels are reviewed, showing a slight increase in creatinine to 1.4 mg/dL and mild hypokalemia, which could be contributing factors to her cardiac symptoms.

The oncology and cardiology teams discuss the necessity of balancing her cancer treatment with her cardiac health. They decide to initiate a low-dose beta-blocker to manage her heart rate and rhythm, while also revisiting her antihypertensive strategy to include a potassium-sparing diuretic, addressing both her blood pressure and electrolyte imbalance. The team also considers erythropoietin-stimulating agents to boost her hemoglobin levels, as her anemia may be impacting her overall cardiovascular stability. These steps aim to stabilize her condition, allowing for the continuation of her chemotherapy with less risk of further cardiac complications. As her treatment progresses, the close monitoring of her cardiovascular and hematologic status remains a top priority, guiding the next steps of her care.

Section 4

Two weeks after the adjustment to her treatment regimen, the patient returns for another follow-up appointment. During the initial assessment, she reports feeling slightly more stable, with a decrease in the episodes of dizziness and palpitations. However, she still experiences fatigue, which affects her daily activities. A physical examination reveals a blood pressure of 145/90 mmHg, indicating a slight improvement, and her heart rate has reduced to 95 beats per minute with regular rhythm, suggesting a positive response to the beta-blocker therapy. Despite these improvements, the patient mentions new symptoms of occasional shortness of breath when climbing stairs and mild swelling in her ankles by the end of the day.

New diagnostic results, including updated blood work and a follow-up echocardiogram, provide further insight. The complete blood count shows her hemoglobin level has increased modestly to 10.2 g/dL, indicating some response to the erythropoietin-stimulating agents, but her red blood cell indices remain low. Her creatinine level has stabilized at 1.3 mg/dL, and her potassium level is now within normal range at 4.0 mEq/L, suggesting the potassium-sparing diuretic is effectively managing her electrolyte balance. The echocardiogram reveals a mild reduction in left ventricular ejection fraction at 50%, raising concerns about potential early cardiac dysfunction secondary to chemotherapy.

In light of these findings, the healthcare team recognizes the need for careful balance and ongoing monitoring of her treatment. The cardiology team suggests an increase in the beta-blocker dosage to further support cardiac function and a closer follow-up schedule to monitor her cardiac status. The oncology team remains committed to continuing her chemotherapy, given the positive response in her cancer markers, but agrees on a multidisciplinary approach to anticipate and manage any emerging complications. Through coordinated care and vigilant assessment, the team aims to maintain her current stability and address any new challenges proactively.

Section 5

Two weeks later, the patient presents for another follow-up appointment, reporting that the shortness of breath has become more frequent and is now accompanied by a persistent, dry cough. She also notices increased fatigue, particularly in the afternoons, which has made her less inclined to participate in her usual activities. During the physical examination, her blood pressure remains stable at 140/88 mmHg, but her heart rate has increased slightly to 105 beats per minute. Auscultation of the lungs reveals faint bilateral crackles at the bases, and an examination of her extremities shows mild pitting edema in both ankles.

Concerned about the new respiratory symptoms and the potential for fluid overload, the healthcare team orders a chest X-ray and additional laboratory tests. The chest X-ray reveals mild pulmonary congestion and a slight increase in heart size, suggesting early signs of heart failure, likely exacerbated by her ongoing chemotherapy regimen. Laboratory results show a mild elevation in BNP (B-type Natriuretic Peptide) levels at 200 pg/mL, further supporting the suspicion of cardiac strain. Her kidney function remains stable with a creatinine level of 1.3 mg/dL, and electrolytes continue to be within normal limits, indicating effective management with the current diuretic therapy.

In response to these findings, the cardiology team decides to adjust her treatment plan by increasing the dosage of her potassium-sparing diuretic and adding a low-dose ACE inhibitor to help reduce cardiac workload and manage fluid retention. The oncology team is informed of these developments to ensure chemotherapy continues without exacerbating her cardiac status. The patient is scheduled for closer follow-up appointments, including regular cardiac evaluations, to monitor for any further changes and to tailor her treatment plan as needed. Through this proactive approach, the healthcare team aims to address the evolving complications while supporting the patient's overall treatment goals.